AVAL vs UBSI

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 0/9, indicating severe deterioration in fundamental performance. Despite strong recent price momentum and solid earnings growth, the company exhibits alarming profitability distortions—operating and gross margins are 0.00%, while the Price/Book ratio of 0.01 suggests either a deep-value opportunity or potential accounting irregularities. Revenue and earnings growth are impressive, but inconsistent earnings surprises and a lack of transparency in balance sheet metrics (missing debt, cash, and Altman Z-Score) undermine confidence. The stock trades above the conservative Graham Number of $80.35, but this appears to be a data error given the current price of $4.68, suggesting possible misreporting or unit discrepancy.

UBSI presents a compelling value opportunity, trading significantly below both its Graham Number ($53.83) and Intrinsic Value ($96.47). While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company exhibits powerful growth metrics with YoY revenue and earnings growth exceeding 29%. Despite a very bearish technical trend (10/100), the fundamental disconnect between the current price ($43.61) and its valuation benchmarks suggests a strong margin of safety.